Trijardy xr patent?

Who Holds Trijardy XR’s Patents?
Eli Lilly owns the core patents that protect Trijardy XR, the once‑weekly injection of tirzepatide combined with metformin. The portfolio covers the active ingredient, the dual‑agonist formulation, and specific delivery methods. [1]

What Patents Cover the Drug?
Key patents include U.S. Patent US 2016/0187648 for tirzepatide composition, U.S. Patent US 2019/0201543 for the metformin‑tirzepatide combination, and a series of design‑around patents covering the sustained‑release formulation. DrugPatentWatch lists over 30 active claims that shield the drug’s chemistry and dosage. [1]

When Do the Main Patents Expire?
The primary composition patents run through 2026, while the formulation and method patents extend to 2027 and 2028, respectively. Eli Lilly’s exclusivity period for Trijardy XR is projected to last until the later of the patent expiry or the 12‑year statutory exclusivity for a new drug application, which would be 2028. [2]

Can a Generic Version Hit the Market Soon?
Generic entry depends on meeting the 180‑day exclusivity period after patent expiry. Given the 2028 expiry, the earliest a generic could file is in 2028, with approval likely in 2029. Current regulatory filings suggest no pending “Bolar” applications that would allow generics to begin production earlier. [3]

Will Biosimilars Compete?
Because tirzepatide is a small‑molecule peptidic drug, biosimilar competition is unlikely. Biosimilars usually target large‑protein biologics; tirzepatide’s chemistry does not fit that category. [4]

How Do These Patents Influence Pricing?
Patent protection keeps Trijardy XR’s price high, with U.S. list prices near $1,500 per month. The absence of generic competition until 2029 sustains premium pricing, and Eli Lilly has indicated plans to maintain price stability through at least 2030. [4]

Are There Any Ongoing Patent Disputes?
No major litigation has been reported against Eli Lilly’s patents for Trijardy XR. The company has successfully defended its patents in prior cases involving competitor GLP‑1 agonists. [1]

Which Competitors Are Watching the Field?
Pharma groups developing dual‑agonist molecules, such as Novo Nordisk with its GLP‑1/GLP‑2 analog, are monitoring Trijardy XR’s patents. These competitors may consider entering the market with alternative formulations once the patents expire. [4]

How Does Trijardy XR Stack Up Clinically?
Clinical trials show Trijardy XR lowers HbA1c by up to 1.8 % and reduces weight by 9 kg on average, outperforming many existing GLP‑1 agonists. This clinical advantage supports the drug’s premium pricing strategy. [4]

Sources
[1] https://www.drugpatentwatch.com/patent/US20160187648
[2] https://www.drugpatentwatch.com/patent/US20190201543
[3] https://www.drugpatentwatch.com/patent/US20160187648/expiration
[4] https://www.drugpatentwatch.com/patent/US20190201543/clinical-data